鼓室内注射地塞米松用于治疗与新型冠状病毒肺炎耐药病例相关的迷路炎
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases.
作者信息
Ismaiel Wael F, Abdelazim Mohamed H, Wahba Ashraf A, Alsobky Mahmoud E, Ibrahim Ahmed Abdalrhman, Ghanem Soliman A, Rabaan Ali A, Ismail Elshahat I
机构信息
Otorhinolaryngology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Audiology Unit, Otorhinolaryngology Department, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
出版信息
Ann Med Surg (Lond). 2022 Sep;81:104429. doi: 10.1016/j.amsu.2022.104429. Epub 2022 Aug 17.
OBJECTIVE
To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19.
METHODS
Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were ordered to continue oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment.
RESULTS
Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 not recovered. In other group; 38/46 patients had complete recovery, 6 had partial recovery and 5/49 patients not recovered.
CONCLUSION
Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy.
目的
评估口服泼尼松龙与鼓室内注射地塞米松（ITID）联合治疗新型冠状病毒肺炎（COVID-19）所致迷路炎的疗效。
方法
纳入75例COVID-19后迷路炎患者。这些患者接受全身口服泼尼松龙治疗两周及ITID治疗。拒绝ITID的患者继续口服泼尼松龙治疗。在治疗后1周、2周、4周以及3个月进行结局评估和听力评估听力测试。
结果
仅口服类固醇组患者26例，口服类固醇和ITID组患者49例。在口服类固醇组中；11/26例患者完全恢复，3/26例部分恢复，12/26例未恢复。在另一组中；38/46例患者完全恢复，6例部分恢复，5/49例患者未恢复。
结论
与仅使用口服皮质类固醇治疗相比，全身使用皮质类固醇联合ITID治疗在COVID-19后前庭障碍和听力损失方面显示出明显改善。
Zotero 插件